Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (82,667)	$ (14,859)	$ 4,134
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	6,434	6,704	6,480
Amortization of acquisition related intangible assets	7,783	7,783	7,837
Amortization of acquisition related inventory step-up	0	0	6,465
Non-cash operating lease cost	2,231	1,850	1,708
Change in fair value of contingent consideration	0	0	(21,095)
Loss on disposal of fixed assets	1,917	0	993
Loss on impairment of intangible assets	62,190	0	600
Stock-based compensation expense	15,243	14,315	11,085
Deferred income taxes	(6,327)	(5,270)	(1,766)
Provision for doubtful accounts	190	378	64
Provision for inventory	3,341	5,329	6,628
Other	0	0	(18)
Changes in operating assets and liabilities:
Accounts receivable	(1,305)	(5,630)	(6,216)
Inventories	(11,396)	(6,873)	(6,619)
Prepaid expenses, other current and long-term assets	560	(792)	1,424
Accounts payable	(11)	1,965	(1,100)
Operating lease liabilities	(2,149)	(1,485)	(1,626)
Accrued expenses, other current and long-term liabilities	1,648	(443)	3,510
Income taxes	530	1,437	(1,311)
Payments of contingent consideration	0	0	(2,780)
Net cash (used in) provided by operating activities	(1,788)	4,409	8,397
Cash flows from investing activities:
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired	0	0	(476)
Proceeds from maturities of investments	0	0	2,501
Purchases of property and equipment	(5,427)	(7,486)	(5,143)
Net cash used in investing activities	(5,427)	(7,486)	(3,118)
Cash flows from financing activities:
Payments made on finance leases	0	(284)	(201)
Repurchases of common stock	(5,000)	0	0
Proceeds from employee stock purchase program	805	665	0
Cash paid for tax withheld on vested restricted stock awards	(2,152)	(934)	(486)
Proceeds from exercises of equity awards	23	16	1,128
Payments of contingent consideration	0	(4,315)	(7,220)
Net cash used in financing activities	(6,324)	(4,852)	(6,779)
Exchange rate impact on cash	79	(130)	69
Decrease in cash and cash equivalents	(13,460)	(8,059)	(1,431)
Cash and cash equivalents at beginning of period	86,327	94,386	95,817
Cash and cash equivalents at end of period	72,867	86,327	94,386
Supplemental disclosure of cash flow information:
Cash paid for income taxes, net of refunds	3,117	106	1,233
Right-of-use assets obtained in exchange for operating lease liabilities	3,239	2,471
Non-cash investing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	815	108	15
Accounting Standards Update 2016-02 [Member]
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 268	$ 11,703	$ 220